-- If Approved, AR101 Will Be the First Medicine for This Life-Threatening Condition -- BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 18, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that the
BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 5, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in three upcoming investor
FDA decision on AR101 BLA filing acceptance expected by end of March Submission of AR101 marketing application in Europe on track for mid-2019 Initiation of AR201 phase 2 trial in egg allergy on track for mid-2019 Company began 2019 with approximately $340 million in cash and investments and
— AR101 Associated with 70% Reduction in Allergic Reactions Due to Accidental Exposures That Required Treatment Compared to Placebo After Dose Escalation in PALISADE — — AR101-Treated Patients Who Completed PALISADE Had 95% Increased Probability of Tolerating Any Dose of Peanut Protein in Exit
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 21, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Thursday, February 28, 2019 , at 5:00 p.m.
— Nine Abstracts Featured, Including Data on Longer-Term AR101 Efficacy and Safety and PALISADE Accidental Exposures — BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 4, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening
— Proven Pharmaceutical Leader Brings Deep, Global Experience with Successful Product Launches, Commercialization and Strategic Planning — BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 18, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially
BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 4, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has entered into a $170 million loan agreement with an affiliate of KKR, a leading
BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 2, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CEO Jayson Dallas , M.D., will present a company overview at the 37 th Annual J.P.
BRISBANE, Calif. --(BUSINESS WIRE)--Dec. 21, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has submitted a Biologics License Application (BLA) to the U.S.
